SS-31 (Elamipretide)

SS-31 is a small, cell-permeable tetrapeptide (D-Arg-2',6'-Dmt-Lys-Phe-NH2) designed to concentrate selectively at the inner mitochondrial membrane by binding cardiolipin, a phospholipid essential for organizing the electron transport chain complexes and mitochondrial cristae architecture. By stabilizing cardiolipin's interaction with cytochrome c and the respiratory chain, SS-31 is reported in preclinical models to reduce electron leakage and reactive-oxygen-species production, limit cardiolipin peroxidation, preserve cristae folding, and support more efficient ATP synthesis — acting as a structural mitochondrial stabilizer rather than a direct free-radical scavenger.

Extensive preclinical evidence across models of aging, heart failure, ischemia-reperfusion injury, kidney disease, neurodegeneration and primary genetic mitochondrial disease supports mitochondrial-protective effects. In humans, the most advanced clinical program is in Barth syndrome (a rare genetic disorder of cardiolipin metabolism), where the TAZPOWER placebo-controlled crossover trial and its 168-week open-label extension reported improvements in 6-minute walk distance, fatigue scores and some cardiac measures. Other clinical programs — heart failure (PROGRESS-HF), primary mitochondrial myopathy (MMPOWER series) and age-related macular degeneration (ReCLAIM) — have produced mixed or inconclusive results. SS-31/elamipretide has not been approved by the FDA, EMA or any other regulator for any indication; it remains an investigational compound studied under the names elamipretide, MTP-131 and Bendavia.

Educational overview only — no dosing instructions in the public hub.

In clinical trials to date, the most commonly reported adverse events have been injection-site reactions with subcutaneous dosing; long-term safety data outside controlled clinical-trial settings are limited, and because it is not approved for any indication, there is no regulatory safety oversight for material obtained outside a trial. Sourcing from non-clinical-trial, non-pharmaceutical channels carries the same purity, sterility and mislabeling uncertainty as any Research-Use-Only peptide.

An independent third-party Certificate of Analysis (CoA) confirming purity by HPLC, accurate peptide quantification against label claim, and mass-spectrometry (MS)-confirmed identity should be considered the minimum verification for any non-clinical-trial material.

Investigational compound only — not approved by the FDA, EMA or any other regulatory agency for any indication as of this review. It holds FDA orphan-drug and fast-track designations for Barth syndrome, reflecting active late-stage development rather than approval. Outside clinical trials, access is limited to material labeled 'Research Use Only (RUO), not for human consumption,' and legal status for that RUO material varies by jurisdiction.